동구바이오제약

006620KOSDAQ

61.2 / 100

Reference Date: 2026-09-08

Financial Score33.0 / 40

News Sentiment17.2 / 25

Momentum7.0 / 20

Disclosure4.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but Operating Profit is on a declining trend. Declined 7.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

DonggubioPharm operates diversified businesses including pharmaceutical manufacturing, new technology investments, marketing services, healthcare services, and pharmaceutical wholesale and consulting. In Q4 2024, its pharmaceutical segment achieved sales of 2,475 billion won, a 15.2% increase compared to the previous year. The company is expanding into new sectors such as biotech investments and medical tourism to enhance growth potential.

Number of Employees

440people

Average Salary

56.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

1.93Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR

0.67Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

38.95Industry Average 8.007.0Point

4.9x industry avg (excellent)

Debt Ratio

30.70Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲6.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼20.1% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 17.3% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 2Neutral 1Negative 1Average Sentiment Score 68.8

Positive
"책임경영 강화"…동구바이오제약, 조직개편 단행
동구바이오제약의 조직개편을 통해 효율적인 경영과 전략 실행력 강화가 기대되어 긍정적인 영향이 예상됩니다.
Positive
동구바이오제약, 피부·비뇨 경쟁력 강화하며 내과까지…본사업 성장...
동구바이오제약은 피부과와 비뇨의학과에서의 강점을 바탕으로 내과까지 사업 영역을 확장하며 성장 잠재력을 높이고 있다.
Negative
'GMP 취소' 불복한 제약사들…재판서도 잇단 패소
동구바이오제약의 GMP 적합 판정 취소 처분에 대한 항소 결정으로 인해 부정적 영향 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 3,595Won52-week high 6,09052-week low 3,450

1-month return1.0Point

1m -7.82% (falling)

Volume trend5.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 2Negative 2

Neutral주식등의대량보유상황보고서(일반)2026-09-02
Negative[기재정정]주요사항보고서(영업정지)2026-08-18
Negative[기재정정]주요사항보고서(영업정지)2026-08-18
Neutral반기보고서 (2026.06)2026-08-12